Physician profile
Manoj Warrier
NPI 1699724161
$315,545.08
in general payments reported to CMS, 2019-2025
32 companies · $72K in 2025
The $72K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $6,289 · 2021: $40K · 2022: $50K · 2023: $39K · 2024: $107K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175K · Travel and Lodging: $25K · Food and Beverage: $11K · Consulting Fee: $7,125 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175,415.00 |
| Travel and Lodging | $25,162.60 |
| Food and Beverage | $10,594.29 |
| Consulting Fee | $7,124.91 |
| Education | $203.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $237,469.07 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $43,661.48 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $15,622.24 | 2021-2024 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $4,793.15 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $4,150.47 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $3,754.24 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,161.21 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Csl Behring | $1,017.92 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $833.50 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $781.59 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $455.83 | 2020-2025 | Xembify, Gamunex-C |
| Ars Pharmaceuticals Operations, INC. | $312.73 | 2025 | Neffy |
| Genentech USA, INC. | $187.39 | 2019-2025 | Xolair |
| Pfizer INC. | $151.60 | 2022-2025 | |
| Pharming Healthcare, INC. | $128.38 | 2022-2024 | Ruconest |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $127.08 | 2019 | |
| Abbvie INC. | $113.06 | 2024 | |
| Organon LLC | $113.02 | 2025 | Vtama |
| Kaleo, INC. | $111.70 | 2020-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $97.85 | 2019-2024 | |
| Biocryst US Sales Co., LLC | $86.23 | 2023-2025 | Orladeyo |
| Hospira, INC. | $67.60 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.80 | 2019-2022 | |
| Horizon Therapeutics Plc | $62.88 | 2020-2022 | |
| Octapharma USA, INC. | $45.50 | 2024 | Octagam Immune Globulin (Human) |
| Aimmune Therapeutics, INC. | $36.19 | 2022 | |
| Optinose US, INC. | $35.95 | 2021-2022 | |
| Blueprint Medicines Corporation | $24.33 | 2024 | Ayvakit |
| Adma Biomanufacturing LLC | $20.66 | 2025 | |
| Merck Sharp & Dohme LLC | $20.00 | 2021 | |
| Bio Products Laboratory USA, INC. | $18.05 | 2023 | Gammaplex, Coagadex |
| Hikma Pharmaceuticals USA | $17.38 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Warrier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.